Femasys (NASDAQ:FEMY) Posts Earnings Results, Beats Estimates By $0.07 EPS

Femasys (NASDAQ:FEMY) posted its quarterly earnings data on Tuesday. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.07, FiscalAI reports. Femasys had a negative net margin of 960.80% and a negative return on equity of 764.26%. The firm had revenue of $0.81 million for the quarter, compared to analysts’ expectations of $1.06 million.

Femasys Trading Up 11.8%

Shares of NASDAQ FEMY traded up $0.04 during midday trading on Tuesday, reaching $0.42. The company had a trading volume of 1,212,277 shares, compared to its average volume of 648,063. The stock has a market cap of $25.38 million, a PE ratio of -0.58 and a beta of -2.53. Femasys has a one year low of $0.31 and a one year high of $1.34. The firm’s fifty day moving average price is $0.54 and its 200-day moving average price is $0.63. The company has a quick ratio of 0.61, a current ratio of 1.16 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

Several analysts have issued reports on FEMY shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Femasys in a research note on Thursday, January 22nd. Lake Street Capital began coverage on shares of Femasys in a report on Tuesday, March 3rd. They issued a “buy” rating and a $1.50 price objective for the company. Finally, Wall Street Zen cut shares of Femasys from a “hold” rating to a “sell” rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Femasys has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Institutional Trading of Femasys

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Kovack Advisors Inc. purchased a new stake in shares of Femasys during the fourth quarter valued at approximately $27,000. HRT Financial LP purchased a new position in shares of Femasys in the fourth quarter worth $30,000. Cetera Investment Advisers bought a new stake in Femasys during the 4th quarter valued at $36,000. Osaic Holdings Inc. bought a new stake in Femasys during the 2nd quarter valued at $45,000. Finally, State Street Corp boosted its position in Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after buying an additional 24,500 shares during the period. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.